Search

Author/Creator Guo, Matthew

1. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). Issue 1 (13th February 2019)

Authors:
Berry, Sneha; Giraldo, Nicolas; Nguyen, Peter; Green, Benjamin; Xu, Haiying; Ogurtsova, Aleksandra; Soni, Abha; Succaria, Farah; Wang, Daphne; Roberts, Charles; Stein, Julie; Engle, Elizabeth; Pardoll, Drew; Anders, Robert; Cottrell, Tricia; Taube, Janis M.; Tran, Ben; Voskoboynik, Mark; Kuo, Jam...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Issue 10028 (16th April 2016)

Authors:
Schöffski, Patrick; Chawla, Sant; Maki, Robert G; Italiano, Antoine; Gelderblom, Hans; Choy, Edwin; Grignani, Giovanni; Camargo, Veridiana; Bauer, Sebastian; Rha, Sun Young; Blay, Jean-Yves; Hohenberger, Peter; D'Adamo, David; Guo, Matthew; Chmielowski, Bartosz; Le Cesne, Axel; Demetri, George D;...
Journal:
Lancet
Issue:
Volume 387:Issue 10028(2016)
Page Start:
1629
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Issue 5 (May 2019)

Authors:
Makker, Vicky; Rasco, Drew; Vogelzang, Nicholas J; Brose, Marcia S; Cohn, Allen L; Mier, James; Di Simone, Christopher; Hyman, David M; Stepan, Daniel E; Dutcus, Corina E; Schmidt, Emmett V; Guo, Matthew; Sachdev, Pallavi; Shumaker, Robert; Aghajanian, Carol; Taylor, Matthew
Journal:
Lancet oncology
Issue:
Volume 20:Issue 5(2019)
Page Start:
711
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Issue 10126 (24th March 2018)

Authors:
Kudo, Masatoshi; Finn, Richard S; Qin, Shukui; Han, Kwang-Hyub; Ikeda, Kenji; Piscaglia, Fabio; Baron, Ari; Park, Joong-Won; Han, Guohong; Jassem, Jacek; Blanc, Jean Frederic; Vogel, Arndt; Komov, Dmitry; Evans, T R Jeffry; Lopez, Carlos; Dutcus, Corina; Guo, Matthew; Saito, Kenichi; Kraljevic, S...
Journal:
Lancet
Issue:
Volume 391:Issue 10126(2018)
Page Start:
1163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Issue 11 (14th April 2018)

Authors:
Wirth, Lori J.; Tahara, Makoto; Robinson, Bruce; Francis, Sanjeev; Brose, Marcia S.; Habra, Mouhammed Amir; Newbold, Kate; Kiyota, Naomi; Dutcus, Corina E.; Mathias, Elton; Guo, Matthew; Sherman, Steven I.; Schlumberger, Martin
Journal:
Cancer
Issue:
Volume 124:Issue 11(2018)
Page Start:
2365
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗